Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CTMX NASDAQ:EDIT NASDAQ:IMVT NASDAQ:SRPT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCTMXCytomX Therapeutics$3.95+3.1%$3.53$1.72▼$8.21$651.82M2.085.57 million shs2.16 million shsEDITEditas Medicine$3.30-10.1%$2.95$1.66▼$4.54$359.32M2.12.68 million shs3.49 million shsIMVTImmunovant$41.09+1.9%$33.40$14.32▼$41.23$8.28B0.761.56 million shs998,566 shsSRPTSarepta Therapeutics$20.52+1.5%$17.79$10.41▼$25.32$2.13B0.213.70 million shs3.01 million shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCTMXCytomX Therapeutics-0.26%+6.39%+30.27%-9.67%+59.58%EDITEditas Medicine-2.13%+11.89%+39.02%+26.99%+28.32%IMVTImmunovant+0.55%+5.69%+30.88%+57.15%+138.66%SRPTSarepta Therapeutics+2.12%+11.04%+29.97%-9.09%+6.20%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCTMXCytomX Therapeutics$3.95+3.1%$3.53$1.72▼$8.21$651.82M2.085.57 million shs2.16 million shsEDITEditas Medicine$3.30-10.1%$2.95$1.66▼$4.54$359.32M2.12.68 million shs3.49 million shsIMVTImmunovant$41.09+1.9%$33.40$14.32▼$41.23$8.28B0.761.56 million shs998,566 shsSRPTSarepta Therapeutics$20.52+1.5%$17.79$10.41▼$25.32$2.13B0.213.70 million shs3.01 million shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCTMXCytomX Therapeutics-0.26%+6.39%+30.27%-9.67%+59.58%EDITEditas Medicine-2.13%+11.89%+39.02%+26.99%+28.32%IMVTImmunovant+0.55%+5.69%+30.88%+57.15%+138.66%SRPTSarepta Therapeutics+2.12%+11.04%+29.97%-9.09%+6.20%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCTMXCytomX Therapeutics 2.91Moderate Buy$12.10206.33% UpsideEDITEditas Medicine 2.57Moderate Buy$5.4063.64% UpsideIMVTImmunovant 2.45Hold$39.70-3.38% DownsideSRPTSarepta Therapeutics 2.08Hold$25.0922.28% UpsideCurrent Analyst Ratings BreakdownLatest SRPT, CTMX, EDIT, and IMVT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/9/2026SRPTSarepta Therapeutics Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$23.00 ➝ $20.007/9/2026SRPTSarepta Therapeutics Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradePeer Perform ➝ Outperform$27.007/7/2026SRPTSarepta Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell7/6/2026IMVTImmunovant Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)6/30/2026IMVTImmunovant CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$57.00 ➝ $61.006/29/2026SRPTSarepta Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D+) ➝ Sell (D)6/16/2026CTMXCytomX Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)6/11/2026SRPTSarepta Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D) ➝ Sell (D+)5/27/2026EDITEditas Medicine TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/26/2026SRPTSarepta Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D+) ➝ Sell (D)5/26/2026IMVTImmunovant GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$44.00 ➝ $62.00(Data available from 7/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCTMXCytomX Therapeutics$76.20M8.82N/AN/A$0.58 per share6.81EDITEditas Medicine$40.52M7.97N/AN/A$0.28 per share11.79IMVTImmunovantN/AN/AN/AN/A$4.19 per shareN/ASRPTSarepta Therapeutics$2.20B0.99N/AN/A$10.89 per share1.88Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCTMXCytomX Therapeutics-$17.37M-$0.41N/AN/AN/A-166.40%-36.61%-28.02%8/6/2026 (Estimated)EDITEditas Medicine-$160.06M-$1.23N/AN/AN/A-281.59%-677.39%-58.25%8/11/2026 (Estimated)IMVTImmunovant-$505.61M-$2.78N/AN/AN/AN/A-65.66%-59.88%8/10/2026 (Estimated)SRPTSarepta Therapeutics-$713.41M-$0.96N/A9.910.21-2.94%7.56%2.94%8/5/2026 (Estimated)Latest SRPT, CTMX, EDIT, and IMVT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2026Q2 2026CTMXCytomX Therapeutics-$0.11N/AN/AN/A$12.39 millionN/A8/5/2026Q2 2026SRPTSarepta Therapeutics$0.4994N/AN/AN/A$383.00 millionN/A5/20/2026Q4 2026IMVTImmunovant-$0.60-$0.73-$0.13-$0.73N/AN/A5/7/2026Q1 2026CTMXCytomX Therapeutics-$0.14-$0.10+$0.04-$0.10$4.68 million$10.26 million5/6/2026Q1 2026SRPTSarepta Therapeutics$0.9760$3.16+$2.1840$2.88$474.16 million$730.80 million5/5/2026Q1 2026EDITEditas Medicine-$0.30-$0.26+$0.04-$0.26$6.37 million$2.83 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCTMXCytomX TherapeuticsN/AN/AN/AN/AN/AEDITEditas MedicineN/AN/AN/AN/AN/AIMVTImmunovantN/AN/AN/AN/AN/ASRPTSarepta TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCTMXCytomX TherapeuticsN/A10.3810.38EDITEditas MedicineN/A3.223.22IMVTImmunovantN/A9.099.09SRPTSarepta Therapeutics0.564.632.62Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCTMXCytomX Therapeutics67.77%EDITEditas Medicine71.90%IMVTImmunovant47.08%SRPTSarepta Therapeutics86.68%Insider OwnershipCompanyInsider OwnershipCTMXCytomX Therapeutics3.80%EDITEditas Medicine3.10%IMVTImmunovant1.80%SRPTSarepta Therapeutics6.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCTMXCytomX Therapeutics170170.19 million163.72 millionOptionableEDITEditas Medicine23097.91 million94.87 millionOptionableIMVTImmunovant120205.31 million201.61 millionOptionableSRPTSarepta Therapeutics1,372105.58 million98.29 millionOptionableSRPT, CTMX, EDIT, and IMVT HeadlinesRecent News About These CompaniesThis Analyst Sees 34% Upside For SRPT Stock — Here's Why They Expect A Sustained Rally NextJuly 9 at 11:47 AM | finance.yahoo.comSarepta Therapeutics (NASDAQ:SRPT) Given New $20.00 Price Target at Piper SandlerJuly 9 at 11:47 AM | marketbeat.comSarepta Therapeutics (NASDAQ:SRPT) Upgraded by Wolfe Research to Outperform RatingJuly 9 at 8:17 AM | marketbeat.comSarepta Therapeutics (NASDAQ:SRPT) Lowered to Strong Sell Rating by Zacks ResearchJuly 9 at 7:35 AM | marketbeat.comY Intercept Hong Kong Ltd Invests $1.94 Million in Sarepta Therapeutics, Inc. $SRPTJuly 9 at 4:31 AM | marketbeat.comSarepta Therapeutics Announces Fourth Quarter and Full-Year 2022 Financial Results and Recent Corporate DevelopmentsJuly 6 at 8:12 PM | finanznachrichten.deSarepta Therapeutics, Inc. (NASDAQ:SRPT) Given Average Recommendation of "Hold" by AnalystsJuly 5, 2026 | americanbankingnews.comSarepta Therapeutics (NASDAQ:SRPT) Raised to "Buy" at Wall Street ZenJuly 4, 2026 | americanbankingnews.comSRPT Stock Climbs After Sarepta Seeks Permanent FDA Nod For Two Duchenne TherapiesJune 30, 2026 | stocktwits.comSSarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 30, 2026 | finance.yahoo.comSarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 30, 2026 | businesswire.comSarepta Moves Closer To FDA Approval For Duchenne Muscular Dystrophy DrugsJune 30, 2026 | benzinga.comSarepta Announces FDA Acceptance of sNDAs for AMONDYS 45® and VYONDYS 53®June 30, 2026 | finance.yahoo.comSarepta Announces FDA Acceptance of sNDAs for AMONDYS 45® and VYONDYS 53®June 30, 2026 | businesswire.comSRPT or PRTA: Which Is the Better Value Stock Right Now?June 24, 2026 | zacks.comSarepta's Elevidys Showing Signs of Stabilization as siRNA Pipeline Gains Importance, RBC SaysJune 18, 2026 | finance.yahoo.comSarepta: Caution Still Warranted Despite FDA's Gene Therapy-Friendly StanceJune 18, 2026 | seekingalpha.comING Groep NV Cuts Stock Holdings in Sarepta Therapeutics, Inc. $SRPTJune 10, 2026 | marketbeat.comAll You Need to Know About Sarepta Therapeutics (SRPT) Rating Upgrade to BuyJune 8, 2026 | finance.yahoo.comIs Sarepta (SRPT) Using New Equity Plans To Quietly Redefine Its Post‑Profitability Playbook?June 8, 2026 | finance.yahoo.comSarepta Therapeutics, Inc. (SRPT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptJune 8, 2026 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesMission Control: Floating In SpaceX's Record-Breaking OrbitBy Jeffrey Neal Johnson | June 15, 2026Uncle Sam Plugs In: Nuclear Energy’s Cash Flow Moment Is Finally HereBy Jeffrey Neal Johnson | June 26, 2026Synchrony’s Comeback Is Hiding in Plain SightBy Peter Frank | June 10, 2026Strategy’s Bitcoin Pivot Gives Investors a New Reason to Watch Preferred SharesBy Jeffrey Neal Johnson | July 5, 2026Bread’s Comeback Is Real—But Is the Easy Money Gone?By Peter Frank | June 17, 2026SRPT, CTMX, EDIT, and IMVT Company DescriptionsCytomX Therapeutics NASDAQ:CTMX$3.95 +0.12 (+3.13%) Closing price 04:00 PM EasternExtended Trading$3.95 0.00 (-0.03%) As of 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.Editas Medicine NASDAQ:EDIT$3.30 -0.37 (-10.08%) Closing price 04:00 PM EasternExtended Trading$3.26 -0.04 (-1.09%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.Immunovant NASDAQ:IMVT$41.09 +0.78 (+1.94%) Closing price 04:00 PM EasternExtended Trading$41.08 -0.01 (-0.02%) As of 07:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.Sarepta Therapeutics NASDAQ:SRPT$20.52 +0.31 (+1.53%) Closing price 04:00 PM EasternExtended Trading$20.41 -0.11 (-0.54%) As of 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas PriceSmart Stock Eyes $220 as Chile Expansion Fuels Growth Lockheed Martin Secures the Ultimate Defense Moat Why Levi's Digital Strategy Is Paying Off in a Big Way Dollar Tree’s Turnaround Is Starting to Take Root Constellation Brands: Beer Growth and Buybacks Mask Stock's Slump Grounded: SpaceX Stumbles as Grok Fails to Ignite Southwest MAX Incident Revives Headline Risk for Boeing and Airline Stocks Fiserv’s Debit Network Talks Raise a Bigger Question for Visa and Mastercard Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
